Table 10.
Summary of the 2-SC in which the antitumoral activity was studied in works using tumor and normal cell lines and description of the observed effects in each type of cells used. The table displays the antitumoral activity shown for the studied 2-SC according to the criterion: selectivity index greater or equal to 2.
| 2-SC | Studied cell lines | Observed effect(s) | Ref. | |
|---|---|---|---|---|
| Tumoral | Non-tumoral | |||
| 1 | Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells | HGF, HPC and HPLF cells | Decreased cell viability of Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells | [64, 66] |
| 30 | Ca9-22, HSC-2, HSC-3 and HSC-4 cells | Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells; and apoptosis induction of HSC-2 cells | [66] | |
| 56 | Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells | |||
| 57 | HSC-2, HSC-3, HSG and HL-60 cells | Decreased cell viability of HSC-2, HSC-3, HSG and HL-60 cells | [64] | |
| 58 | MCF-7, NCI-H460, Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells | MRC-5 cells, human lymphocytes, HGF, HPLF and HPC cells | Growth inhibition of MCF-7 and NCI-H460 cells; cell cycle arrest at the G2/M phase of MCF-7 and NCI-H460 cells; microtubule-stabilizing antimitotic effect in MCF-7 and NCI-H460 cells; weak inhibition of peripheral human lymphocytes proliferation; decreased cell viability of Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells; apoptosis induction of HSC-2 cells; DNA fragmentation induction in HL-60 and HSC-2 cells; and activation of caspase 3, 8 and 9 in HL-60 cells | [64–66] |
| 88 | Ca9-22, HSC-2, HSC-3 and HSC-4 cells | HGF, HPLF and HPC cells | Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells | [66] |
| 92 | Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells | Decreased cell viability of Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells | [64, 66] | |
| 103 | HSC-2, HSC-3, HSG and HL-60 cells | Decreased cell viability of HSC-2, HSC-3, HSG and HL-60 cells; DNA fragmentation induction in HL-60 and HSC-2 cells; and activation of caspase 3, 8 and 9 in HL-60 cells | [64] | |
| 104 - 108 | Ca9-22, HSC-2, HSC-3 and HSC-4 cells | Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells | [66] | |
| 110, 111 | ||||
| 114, 115 | ||||
| 152 | AREc32 and K562 cells | Peripheral blood mononuclear cells | Nrf2-inducing activity in AREc32 cells; decreased cell viability and proliferation of K562 cells | [70] |
AREc32: human mammary epithelial adenocarcinoma cell line; Ca9-22: human oral squamous cell carcinoma Ca9-22; HGF: human gingival fibroblast; HL-60: promyelocytic human leukaemia-60 cell line; HPC: human pulp cell; HPLF: human periodontal ligament fibroblast; HSC-2: human squamous cell carcinoma-2; HSC-3: human squamous cell carcinoma-3; HSC-4: human squamous cell carcinoma-4; HSG: human submandibular gland carcinoma; K562: human chronic myeloid leukaemia; MCF-7: breast adenocarcinoma cell line; MRC-5: diploid embryonic lung fibroblast cell line; NCI-H460: non-small cell lung cancer; Nrf2: nuclear factor erythroid 2-related factor 2.